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1. Introduction 
The lung is the human organ most susceptible to oxidative damage. The transition from 
fetal, a low-oxygen environment, to FiO2: 0.21, induces a relative degree of oxidative stress 
for all newborns, but especially in the case of preterm neonates whose lung development 
has been interrupted. A supplementary supply of oxygen (hyperoxia) is often used to treat 
preterm newborns and these infants may not yet be prepared to protect their lungs from 
oxidative injury. 
One of the most important advances in neonatal care has been the introduction of antenatal 
corticosteroid therapy for preventing respiratory distress syndrome and improving the 
survival of preterm infants (Liggins et al., 1972; 1995). Foetal and postnatal lung 
development is regulated by glucocorticoids (Speirs et al., 2004).  
During lung development, vascular endothelial growth factor (VEGF) is an important growth 
factor in vasculogenesis and angiogenesis (Voelkel et al., 2006), and it plays a central role in 
epithelial-endothelial interactions, which are critical for normal lung development (Zhao et al., 
2005). VEGF is also involved in alveolarization (Thebaud et al., 2005), and it has been reported 
that the inhibition of VEGF impairs this process (Zhao et al., 2005; Van Tuyl et al. 2005).  
Situations such as hypoxia, hyperoxia, and the administration of antenatal corticosteroids 
may regulate VEGF expression and may interfere with the alveolarization process (Remesal 
et al. 2009, 2010; San Feliciano et al., 2011). 
Among the mechanisms implicated in lung damage due to hyperoxia, alterations in the 
expression of pulmonary VEGF have been described (Roberts et al., 1983; Maniscalco et al., 
2005; Remesal et al., 2009). In our previous experimental studies in rats, we have also 
observed that dexamethasone and hyperoxia have an additive effect on the inhibition of 
VEGF, with a decrease in alveolarization (Remesal et al., 2010). 
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In this chapter we shall discuss the importance of vasculogenesis and angiogenesis in lung 
development, the role of VEGF in lung development, the effect of oxidative stress on the 
pulmonary expression of VEGF and alveolarization, the effects of antenatal glucocorticoids 
added to oxidative stress on the pulmonary expression of VEGF and alveolarization and, 
finally, the role of VEGF in the pathogenesis of bronchopulmonary  dysplasia (BPD). 
2. Angiogenesis and vasculogenesis in lung development 
Vascular development occurs during all stages of lung development. The formation of the 
pulmonary vasculature includes three processes: angiogenesis, which leads to central 
vessels by the budding of new vessels from previous ones; vasculogenesis, which results in 
peripheral vessels by in situ differentiation of mesenchymal cells into hemangioblasts, and 
the fusion between the central and peripheral systems, creating the pulmonary circulation 
(Papaioannou et al., 2006; Akeson et al., 2000).  
Vascular development in the lung has been shown to be a determinant of the maturation of 
lung structure, and angiogenesis and vasculogenesis are necessary for the successful 
development of the organ (Voelkel et al., 2006). 
Interactions between the airways and blood vessels are critical for normal lung 
development, suggesting that a coordinated and timely release of vascular growth factors 
would promote alveolar development (Thebaud et al., 2005). 
Jakkula et al. (Jakkula et al., 2000) administered antiangiogenic agents, SU-5416, thalidomide 
and fumagillin, to neonatal rats and observed a decrease in alveolarization and lung growth, 
with a histological pattern similar to BPD. 
Van Tuyl et al.(Van Tuyl et al., 2005) found that the inhibition of vascularization in vitro 
resulted in a significant decrease in the morphogenesis of the airways, suggesting that 
pulmonary vascular development would be a factor in lung morphogenesis.  
Schwarz et al.(Schwarz et al., 2000) reported that the inhibition of neovascularization with 
endothelial monocyte-activating polypeptide II (EMAP II) resulted in an arrest in the 
morphogenesis of the airways. It has also been reported that pulmonary vascular 
development is dependent on reciprocal interactions with the lung epithelium. Gebb and 
Shannon (Gebb et al., 2000) showed that mesenchymal cells cultured in the absence of 
epithelial cells degenerate, and they also observed significantly fewer cells positive for 
VEGFR-2 (VEGF receptor 2). In contrast, lung mesenchyme recombined with lung epithelial 
cells contained abundant cells positive for VEGFR-2, and their spatial distribution was 
similar to that observed in vivo in the lungs of foetal and neonatal rats. In an in vivo study 
of the lung, they found, as from foetal day 11, precursor cells with a positive expression of 
VEGFR-2 in the mesenchyme in the developing epithelium.  
Studies carried out by Burri (Burri, 2006) have shown that in the human lung microvascular 
maturation begins very early and partly takes place during alveolarization, ending at an age 
of 2-3 years.  
Genetic analyses have shown that cell-cell interactions and cell-extracellular matrix, growth 
factors and transcription factors are involved in vascular development (Roth-Kleiner et al., 
2003).  
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One of the most important factors related to the processes described above is clearly VEGF 
(Thebaud et al., 2005).  
3. The role of VEGF in lung development 
Vascular endothelial growth factor (VEGF) is a potent mitogen for endothelial cells (Ferrara 
et al., 1997; Lassus et al., 1999) as well as being chemotactic for these cells, and it is one of the 
most potent mediators of vascular regulation (Bhatt et al., 2000). Regarding water and 
proteins, VEGF exerts a potent effect on vascular permeability (Dvorak et al., 1995). VEGF is 
also necessary for the survival of endothelial cells, especially in hyperoxic environments 
(Watkins et al., 1999; Maniscalco et al., 2002). 
In 1996, the studies of Ferrara et al (Ferrara et al., 1996) and Carmeliet el al. (Carmeliet et al., 
1996) revealed the critical role of VEGF in embryonic vasculogenesis and angiogenesis. Those 
authors observed the death of mouse embryos, with the inactivation of a single VEGF allele.  
The VEGF signalling pathway is important in vasculogenesis, particularly during foetal 
lung development (Gebb et al., 2000; Voelkel et al., 2006) . The expression of VEGF and 
VEGFR-2 has been demonstrated in airway tube and vascular mesenchymal cells during 
foetal development and also in vitro in cultures containing epithelial and mesenchymal 
elements of  foetal  lung (Gebb et al., 2000). 
In baboons, Maniscalco et al. (Maniscalco et al., 2002) found an association between 
increased PECAM-1 (platelet endothelial cell adhesion molecule) and increased VEGF 
levels, suggesting a role of VEGF in pulmonary vasculogenesis. 
Lassus et al (Lassus et al., 2001) found a higher concentration of VEGF in tracheal aspirates 
of preterm infants than in those from term infants. Levy et al (Levy et al., 2005) reported that 
in foetal lungs VEGF expression was higher in the canalicular and saccular stages.  
In a murine model, Bhatt et al. (Bhatt et al., 2000) observed that VEGF mRNA levels 
increased three-fold during the first two weeks of postnatal age: i.e., the alveolarization 
phase and expansion of the microvasculature; VEGFR-2 mRNA increased in parallel. In 
those studies, performed by in situ hybridization, the authors demonstrated that VEGF 
mRNA was mainly located in the epithelial cells of the distal air spaces. 
The mRNA expression of VEGFR-1 and VEGFR-2 also increases during normal lung 
development in mice (Costa et al., 2001; Gebb et al., 2000), and these receptors are located on 
the endothelial cells of pulmonary vessels in proximity to the epithelium in development. 
This spatial relationship suggests that VEGF would play an important role in the 
development of the alveolar capillary bed. 
Del Moral et al. (Del Moral et al., 2006) described that exogenous VEGF164 induces bronchial 
morphogenesis in cultured embryonic mouse lung. The effect of VEGF on the epithelium 
would be indirect, through an interaction with the mesenchyme, because these authors only 
found VEGFR-2 to be expressed in mesenchymal cells. 
The expression of VEGF mRNA and VEGF protein is localized to distal epithelial cells in 
human foetal lung during the second half of pregnancy  and its levels increase with time 
(Brown et al., 2001). 
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More recently, in humans Groenman et al. (Groenman et al., 2007)  observed the expression 
of VEGF in the epithelium during the first trimester, as well as the expression of VEGFR-2 in 
mesenchymal cells adjacent to the epithelium and mesenchyme in vascular structures. 
In a mouse model with lung renal capsule grafts, Zhao el al (Zhao et al., 2005) identified the 
role of VEGF in lung development. By inhibiting VEGF they observed the inhibition of 
vascular development and a significant alteration  in epithelial development. 
The absence of VEGF164 and VEGF188 isoforms results in a decrease in peripheral vascular 
development and a delayed formation of air spaces in mouse lungs (Van Tuyl et al., 2005). 
It has been shown that the inhibition of VEGF results in the inhibition of angiogenesis and 
alveolarization in lung development in rats. The inhibition of VEGF for even short periods 
of time may also reduce the number of blood islands and endothelial cells expressing 
VEGFR-2 (Van Tuyl et al., 2005). 
Thebaud B et al. (Thebaud et al., 2005) performed in vitro and in vivo studies in rat lung, 
reporting that the inhibition of the VEGF signal stopped alveolarization, offering  a model 
similar to BPD and emphysema. 
Use of SU-5416, which blocks the VEGF receptor, before or after birth results in a reduction 
in pulmonary vascularization and alveolarization (Jakkula et al., 2000). 
Reports have been made of the existence of a regulatory loop in which epithelium-derived 
VEGF induces vascular development and endothelial relayed signals directly or indirectly, 
via the mesenchymal compartment, and stimulates epithelial differentiation and branching 
(Van Tuyl et al., 2005). 
According to the studies carried out by Yamamoto et al. (Yamamoto et al., 2007) primary 
septum formation depends on interactions between the respiratory epithelium and the 
underlying vessels, suggesting a dependence of the development of pulmonary capillaries 
on the VEGF-A derived from the epithelium.  
In human foetal lung cell cultures in the second half of gestation, Brown et al (Brown et al., 
2001) found the VEGFR-2 receptor and neurofilin I in epithelial cells, suggesting a possible 
autocrine role of VEGF in the proliferation and differentiation of human alveolar epithelial 
cells. They also observed that exogenously administered VEGF increased tissue 
differentiation parameters and that this led to a proliferation of epithelial cells in the distal 
airways with the morphology of type II pneumocytes and, additionally, it increased the 
production of several components of surfactant. 
VEGF stimulates the production of pulmonary surfactant by type II pneumocytes (Voelkel 
et al., 2006; Papaioannou et al., 2006; Ferrara et al., 2003), leading to lung maturation and 
preventing the development of respiratory distress syndrome in newborns. 
Compernolle  et al (Compernolle et al., 2002) performed a study in premature mice in which 
they observed an increase in the production of surfactant proteins B and C after treatment 
with VEGF, showing that type II cells express VEGFR-2. Although the precise mechanisms 
by which VEGF stimulates the synthesis of surfactant have not been clearly defined, it 
appears that VEGF stimulates the synthesis of platelet-activating factor (PAF), a potent 
inducer of glycogenolysis in the foetal lung, and activates kinase C protein, a central 
regulator of surfactant secretion and glycogen metabolism. 
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It has been reported that the inhibition of VEGF results in endothelial cell death, suggesting 
that VEGF could also be a survival factor for endothelial cells (Maniscalco et al., 2005).  
4. Effects of oxidative stress on pulmonary VEGF expression and 
alveolarization 
Some studies have shown the involvement of reactive oxygen species (ROS) in the mitogenic 
cascade initiated by tyrosine kinase receptors of many growth factors. Colavitti et al 
(Colavitti et al., 2002) identified reactive oxygen species as mediators involved in the signal 
transduction of VEGFR-2; these findings were paradoxical, however, because it is well 
known that angiogenesis occurs at low oxygen concentrations. Nevertheless, situations of 
complete anoxia are very rare under physiological conditions. Other  studies have shown 
that low oxygen concentrations give rise to oxygen free radicals through a mechanism 
involving an abnormal flow of electrons in the respiratory mitochondrial chain (Chandel et 
al., 1998). 
Preterm birth in ambient air, before the full development of antioxidant defences, elicits a 
relative degree of hyperoxia, which blocks normal lung vascular development and 
alveologenesis (Massaro et al., 2004; Thebaud, 2007). 
The perinatal period is critical for proper adaptation to postnatal lung life. Lung damage 
during the perinatal period could interfere with lung growth, leading to abnormalities in 
lung structure and function that persist in children and adults. Premature infants with 
immature lungs often require high inspired oxygen levels, which are toxic to alveolar and 
endothelial cells (Crapo, 1986, 2003a, 2003b). Studies carried out by our group and other 
researchers have shown that hyperoxia alters alveolar growth by interfering with essential 
growth factors such as VEGF (Maniscalco et al., 1997; Remesal et al., 2009, 2010). 
In our studies (Remesal et al., 2009, 2010) we evaluated pulmonary VEGF expression by RT-
PCR and immunohistochemistry with densitometry analysis in Wistar rats at 0, 4 and 14 
days of life. In order to analyse alveolarization, quantitative morphometric assessment was 
carried out by superimposing a sample over a square grid pattern (model CPLW 1018, Zeiss 
Optical, Hannover Md) for conventional haematoxylin-eosin lung preparations (Blanco et 
al., 1994), and the mathematical model of Weibel (Weibel et al., 1966) was applied, 
measuring Lm (mean air space size), Nv (number of alveoli) and  ISA (mean internal surface 
area). All procedures were approved by the Animal Health Care Committee of the 
University of Salamanca. The experiments were performed following the regulations of the 
Directive of the Council of the European Community (DOCE L 222; 24/08/1999). The rats 
were born at 21-22 days of gestation by natural delivery and were mixed and randomly 
distributed in a litter size adjusted to 8 pups in order to control for the effects of this on 
nutrition and growth (Crnic, L. S. et al., 1978). Rat pups were exposed to hypoxia for two 
hours (0.10 FiO2) at 4-8 hours of life in a sealed chamber with continuous O2 monitoring 
(SERVOMEX 1440 gas analyser) and then recovered for a further 2 hours under hyperoxia 
(>0.95 FiO2) (hyperoxia after hypoxia group) or normoxia (room air, 0.21 FiO2 ) (normoxia 
after hypoxia group) or not recovered (hypoxia group). The rat pups studied at 4 and 14 
days were later maintained in room air. The animals of the control group were under 
normoxic conditions throughout the study.  
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In our studies (Remesal et al., 2009, 2010), we observed a decrease in pulmonary VEGF 
expression in rats that were exposed to hyperoxia after hypoxia and this finding correlated 
with less alveolar septation. We observed that pulmonary VEGF expression remained 







C: Control. B: Betamethasone. D: Dexamethasone. A: Air. HA: Hypoxia + Air. HH: Hypoxia + 
Hyperoxia 
Fig. 1. Immunohistochemistry. Lung sections for each group. 
The effect of hyperoxia on the postnatal lung varied, depending on the length of exposure, 
the degree of hyperoxia, and the age and animal species used in the model. In mice, 
McGrath-Morrow et al. (Grath-Morrow et al., 2005) found differences between the lung 
damage caused by hyperoxia and damage due to blocking VEGFR-2. In lungs exposed to 
hyperoxia the damage was more persistent; the animals had a more reduced mitotic index 
and showed increased apoptosis. 
Roberts et al.(Roberts et al., 1983) reported that newborn rats exposed to an FiO2 of 1 
exhibited a decrease in the number of capillaries due to the toxic effect of oxygen on 
endothelial cells. Kunig et al. (Kunig et al., 2005) found that lungs subjected to hyperoxia 
had a decreased number of alveoli and showed reduced vascular growth. 
Although hyperoxia could inhibit lung growth through several mechanisms, clinical and 
experimental studies have suggested that damage to VEGF signalling plays an important 
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role in the pathogenesis of BPD (Thebaud et al., 2005,; Kunig et al., 2005; Maniscalco et al., 
2002;Lin et al., 2005; Thebaud, 2007). In many studies it has been shown that hyperoxia 
decreases VEGF levels. 
Thebaud B et al.(Thebaud et al., 2005) described irreversible hypoalveolarization induced by 
oxygen in rat lung development, and this was associated with decreased VEGF expression 
and reduced vascular growth. 
Wageenaar et al (Wagenaar et al., 2004) investigated gene expression by analysing 
"microarray" DNA in the lungs of preterm rats exposed to prolonged hyperoxia, observing a 
decrease in VEGF levels and those of its receptor VEGFR-2. 
Endothelial cells are particularly sensitive to oxidative stress and decreases in VEGF levels 
due to hyperoxia further increase the susceptibility of the epithelium to hyperoxic injury 
and a greater loss of these cells after acute hyperoxia (Kunig et al., 2005;  Lin et al., 2005). 
During exposure to hyperoxia, a destruction of the lung microvascular system was 
observed, accompanied by a cessation of endothelial regeneration, which is essential for the 
repair of lung injury induced by oxygen (Watkins et al., 1999). 
Klekamp et al. (Klekamp et al., 1999) reported a reduction in VEGF in the lungs of rats 
exposed to hyperoxia (FiO2> 0.95 between postnatal days 6 and 14) associated with alveolar 
cell apoptosis and a reduced expression of VEGFR-2 and VEGFR- 1. 
Maniscalco et al. (Maniscalco et al., 2002) found that preterm baboons treated with oxygen 
had a 70% decrease in PECAM-1 protein and a 27% decrease in capillary density in the 
presence of dysmorphic capillaries in comparison with a control group. They observed a 
decrease in VEGF mRNA, supporting the hypothesis that the development of BPD could be 
the result of a disruption of the genetic program of angiogenic factors and receptor 
expression in endothelial cells. 
Watkins et al. (Watkins et al., 1999) found that in damage due to hyperoxia in newborn and 
adult rabbits the proportion of VEGF189 decreased, normal values being re-established 
during recovery under normoxic conditions.  
In a model of hyperoxia exposure in mice, Zimova et al (Zimova-Herknerova et al., 2008) 
observed a decrease in VEGF mRNA levels that was lower when the animals were given 
retinoic acid. 
The decrease in VEGF expression in hyperoxia could be related to the suppression of the 
expression of hypoxia-induced factor 2- (HIF2-α or HLF) (Maniscalco et al., 2002). 
Moreover, hypoxia-induced factor (HIF) is inhibited by increasing levels of oxygen 
(Thebaud, 2007). 
In a study carried out on newborn rats, Hosford  et al (Hosford et al., 2003) showed that the 
expression of VEGF, VEGFR-1 and VEGFR-2 was decreased at 12 and 14 days after exposure 
to a hyperoxic environment during the critical period of alveolar development (4 to 14 
days). They observed that under conditions of normoxia there was a strong correlation 
between VEGF and HLF. This correlation disappeared after hyperoxia, suggesting that low 
levels of HLF, after exposure to high concentrations of O2, would not stimulate the 
expression of VEGF. 
www.intechopen.com
 
Oxidative Stress – Molecular Mechanisms and Biological Effects 
 
180 
Roper et al. (Roper et al., 2004) found that alveolar type II epithelial cells exposed to 
hyperoxia showed DNA damage (broken strands, modifications of bases, changes in sister 
chromatids and the oxidation of guanine to 8-oxoG), even though they were 
morphologically intact. Hyperoxic injury was produced by the interaction of ROS with 
macromolecules such as DNA, lipids and proteins.  
 Oxidative damage to tissues could be exacerbated by damage to VEGF signalling. It has 
been observed that VEGF induces manganese superoxide dismutase (MnSOD) and nitric 
oxide (NO), both of which are scavengers of reactive oxygen species (Maniscalco et al., 
2005). In VEGF-overexpressing transgenic mice, Siner et al (Siner et al., 2007) have shown 
that VEGF induces cytoprotection via the induction of heme oxygenase-1 (an antioxidant) 
and also that VEGF has the capacity to decrease levels of apoptosis markers.  
In addition VEGF conferred cytoprotection through an A1-dependent mechanism, a critical 
regulator in lung injury and cell death induced by hyperoxia. He et al. (He et al., 2005) 
showed that transgenic VEGF165-overexpressing mice had increased A1 protein levels and 
A1 mRNA and that they survived longer under conditions of hyperoxia with a FiO2 of 1. 
In a study of preterm baboons subjected to hyperoxia for 6 to 10 days, Maniscalco et al. 
(Maniscalco et al., 2005) found an increase in the levels of p53, a transcription factor that 
represses VEGF transcription, in distal epithelial cells. They also found oxidant DNA 
damage with increased 8-oxoG levels, which would be the mechanism responsible for the 
increase in p53 level. 
In a study performed with mice to detect alveolar type II cells, Yee et al. (Yee et al., 2006) 
observed a loss of these cells after exposure to hyperoxia; this would be related to the  
decrease in VEGF levels in hyperoxia. 
In studies by Maniscalco et al. (Maniscalco et al., 1995, 2002) it has been reported that VEGF 
is expressed in type II cells with low surfactant protein C levels. Thus, the change in the 
distal epithelial cell phenotype was seen in situations of hyperoxia, with more cells with 
high amounts of surfactant protein C, resulting in a decrease in the production of VEGF. 
It has also been shown that oxidative stress inactivates the survival signal of VEGF in 
endothelial cells through the action of peroxynitrite (Acarregui et al., 1999) . 
Furthermore, in vitro and in vivo studies have described the induction of VEGF by reactive 
oxygen species. In ferrets, Becker et al  (Becker et al., 2000) reported an increase in VEGF in a 
model of lung ischemia, regardless of exposure to  oxygen, and in a mouse model Corne et 
al. (Corne et al., 2000) observed an increase in VEGF levels in bronchoalveolar lavage fluid 
after 72 hours of exposure to an FiO2  concentration of 1. 
In our studies (Remesal et al., 2009, 2010) the animals were previously exposed to acute 
hypoxia. It has been described that early exposure to hypoxia predisposes the animals to an 
increased response to any further damage (Haworth et al., 2003). Saugstad (Saugstad, 1988) 
reported that reoxygenation following hypoxia generated an increase in oxygen free radicals 
levels that could not be neutralized by antioxidant defences and that resulted in injury to 
cellular structures. Ekekezie et al. (Ekekezie et al., 2003) and Lin et al. (Lin et al., 2005) 
reported that hyperoxia negatively regulates the expression of VEGF, despite recovery in 
air. These findings are similar to our own. 
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5. Antenatal glucocorticoids  
One of the most important advances in neonatal care has been the introduction of antenatal 
glucocorticoid therapy for preventing respiratory distress syndrome and improving the 
survival of preterm infants (1995). Foetal and postnatal lung development is regulated by 
glucocorticoids (Speirs, H. J. et al., 2004). There are many reports showing that corticoids can 
alter the normal stages of lung development during the period of alveolarization. Corticoids 
are known to trigger the structural maturation of mesenchymal cells and the functional 
maturation of the surfactant system (Jobe, A. H., 2001).  
Dexamethasone and Betamethasone are the only corticosteroids recommended for antenatal 
therapy ( National Institute of Health NIH, 1995), and as yet there are no indications 
favouring the use of one preparation over the other (Crowley, 2007), although there are 
some reports giving preference to bethametasone (Lee et al., 2006; Miracle et al., 2008; 
Remesal, et al., 2010; San Feliciano et al., 2011). The dosage and number of treatment cycles 
in gestating women at risk of preterm delivery are still under debate because of the long-
term effects of these drugs on growth (Sweet et al., 2010).  
5.1 Effects of betamethasone vs dexamethasone on the expression of VEGF and 
alveolarization 
Massaro et al. (Massaro et al., 2004) reported that in all species septation, whether antenatal 
or postnatal, occurs during a period in which the plasma concentration of glucocorticoids is 
low and that it ends when the concentration of glucocorticoids increases. Also, in studies 
performed by Liu et al. (Liu et al., 2004) the authors showed that dexamethasone inhibits 
IGF-I, this having an impact on alveolarization.  
Studies by Massaro (Massaro et al., 2004) and Clerch (Clerch et al., 2004) have shown that 
glucocorticoid administration to rats or mice during the period of septation, when the 
plasma concentration of steroids is usually low, damages spontaneous septation and the 
development of the pulmonary vasculature. There was no further spontaneous septation 
and vasculogenesis when steroid treatment was withdrawn (tested in rats up to 95 days). 
This observation suggests that there would be a critical period for the development of these 
events. In those studies, using microarray analysis of pulmonary gene expression the 
authors identified a negative regulation of VEGFR-2 by dexamethasone, resulting in the 
inhibition of septation.  
Furthermore, in a study in newborn rats treated with steroids during the first 4 days of life 
Tschanz et al. (Tschanz et al., 2003) have shown that the lung has the ability to recover from 
the damage caused by steroids when these are suspended. 
In our studies (Remesal et al., 2010; San Feliciano et al., 2011), in order to evaluate possible 
differences between the effect of both antenatal glucocorticoids, dexamethasone, 
betamethasone or saline solution were administered intravenously to pregnant Wistar rats 
on the 20th and 21st days of gestation. The newborn rats were exposed to the different 
experimental situations described previously. 
We observed a decreased pulmonary VEGF expression that was correlated with a decrease 
in alveolarization in the animals that received antenatal dexamethasone. This effect on 
VEGF and alveolarization was not found in the animals that received antenatal 
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betamethasone (Fig.1). We observed a negative effect on lung maturation and VEGF 
expression caused by antenatal dexamethasone lasting from the saccular phase until the end 
of the alveolarization period (Remesal et al., 2010; San Feliciano et al., 2011).  
The only structural difference in the molecule of these two corticosteroids is the orientation 
of the methyl group at position 16, and this small difference seems to have important 
consequences. Other authors have reported the different biological effects of both 
corticosteroids. Rayburn et al. (Rayburn et al., 1997) observed better memory in rats treated 
with antenatal betamethasone and poorer memory in the group treated with antenatal 
dexamethasone.  
In an in vitro study of thymocytes, Buttgereit et al (Buttgereit et al., 1999) observed that 
different glucocorticoids, including dexamethasone and betamethasone, differed in the 
strength of their genomic and non-genomic effects; they found that dexamethasone was five 
times more potent in inhibiting cellular respiration. 
Other authors have reported differences in genomic and non-genomic effects between the 
two molecules and the expression of NMDA receptors (McGowan et al., 2000; Setiawan et 
al., 2007) and in the expression of the sodium channels of respiratory epithelial cells. 
Although we have found no reports comparing the effects of betamethasone or 
dexamethasone on lung VEGF, our results indicate that the molecules do have different 
actions (Remesal et al., 2010; San Feliciano et al., 2011). 
In clinical studies, different findings have been reported with the use of either molecule 
(dexamethasone or betamethasone). Baud et al (Baud et al., 1999) published a multicenter 
study with a cohort of 883 children with gestational ages of 24 to 31 weeks over a period of 4 
years. The mothers of 361 infants had received betamethasone; the mothers of 165 infants had 
received dexamethasone, and the mothers of 357 children had not received glucocorticoids. 
The authors compared the frequency of cystic periventricular leukomalacia among the three 
groups using a multivariate analysis adjusted for confounding factors such as sex, 
chorioamnionitis, infection, multiple gestation, and other relevant factors. 8.4% of children in 
the group that had not received antenatal steroids developed cystic periventricular 
leukomalacia as compared to 4.4% of the children in the antenatal betamethasone-treated 
group and 10.9% of those in the antenatal dexamethasone-treated group. 
In the study by Lee et al. (Lee et al., 2006), which included 3600 children with birth weights 
of less than 1500 grams, the authors found a decrease in mortality in the children who had 
received antenatal betamethasone as compared with the group that had not received 
antenatal steroids; they failed to find this decrease in mortality in the antenatal 
dexamethasone-treated group. Also, dexamethasone was associated with an increase in 
neonatal mortality as compared with betamethasone. They found a lower incidence of 
severe retinopathy in children who had received antenatal betamethasone and this would be 
related to the inhibition of TNF-α. This factor was also involved in angiogenesis. In that 
study, the authors also observed a lower frequency of intraventricular hemorrhage in 
children who had received antenatal betamethasone. Similar results have also been 
published in the Cochrane meta-analysis reported by Crowley (Crowley, 2007). 
Feldman et al. (Feldman et al., 2007) reported a study of 334 preterm infants with birth 
weights of less than 1500 grams at birth: 186 children had received antenatal betamethasone 
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and 148 had received antenatal dexamethasone. The most important finding observed in 
that study was that the children who had received antenatal betamethasone had a lower 
incidence of respiratory distress syndrome and BPD. 
In cultured embryonic rat lung, Oshika E et al (Oshika et al., 1998) showed that treatment 
with dexamethasone resulted in growth retardation, abnormal branching, dilated proximal 
tubules, and a suppression of the proliferation of the epithelial cells of the distal tubules.  
Schellenberg and Liggins (Schellenberg et al., 1987) administered dexamethasone to 
pregnant rats and studied its effects on lung development in the offspring during foetal and 
postnatal life. The results revealed an inhibition of lung growth and body growth, and a 
reduction in DNA contents in the animals treated with dexamethasone. Dexamethasone 
appeared to affect the populations of cells that produce elastin and cells that produce 
collagen during foetal lung development.  
In in vitro studies of human lung fibroblast cultures, it was observed that dexamethasone 
inhibited fibroblast proliferation and chemotactic activity in a dose-dependent manner 
(Brenner et al., 2001).  
There are different studies, such as ours, describing a relationship between steroids and 
VEGF. In studies carried out by Vento et al.(Vento et al., 2002) on preterm infants, the 
authors found that lung VEGF levels were decreased in the dexamethasone-treated group as 
compared with the untreated group.  
Many in vitro studies (Nauck et al., 1997; Nauck et al., 1998; Harada et al., 1994; Tanabe et 
al., 2006) have described a strong negative regulation of the induction of VEGF expression 
by dexamethasone  in different cell types, including alveolar epithelial cells.  
Hewitt et al (Hewitt et al., 2006) showed that VEGF expression was decreased in the 
placentas of pregnant rats  treated with dexamethasone. 
In an in vitro study, Gille et al (Gille et al., 2001) found that in human keratinocyte cells 
treated with glucocorticoids  VEGF mRNA was rapidly degraded within 2 hours. The 
decrease in mRNA stability could be one mechanism of glucocorticoid-induced inhibition of 
VEGF. 
In an in vitro study of human foetal lungs, Acarregui et al. (Acarregui et al., 1999) found 
increased levels of VEGF mRNA when the lung tissue was maintained in dexamethasone 
for 4 days as from the onset of incubation in 0.20 FiO2. However, when the epithelium was 
first incubated in FiO2 0.20 and then treated with dexamethasone, mRNA levels were not 
increased. According to those authors, dexamethasone induced differentiation in type II 
cells and this was responsible for the variations in the levels of VEGF.  
In studies of preterm infants, Lassus et al. (Lassuset al., 1999, 2001) found no differences in 
the concentration of VEGF in tracheal aspirates from children who had received antenatal 
steroids and those who had not. They also failed to find any differences in the concentration 
of VEGF in preterm infants treated early on with postnatal dexamethasone.  
Moreover, D'Angio et al. (D'Angio et al., 1999) have described higher levels of VEGF in 
tracheal aspirates in preterm infants treated with dexamethasone.  
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In a study carried out in mice, Compernolle et al. (Compernolle et al., 2002) observed that 
antenatal dexamethasone stimulated the expression of foetal VEGF when administered at 
low doses (0.8 mg / kg), but suppressed the production of VEGF when administered at high 
doses ( 2.4 mg / kg). Thus, excessive amounts of glucocorticoids could neutralize the 
beneficial effects of VEGF in the lung. 
Conversely, a study in mice conducted by Bhatt et al. (Bhatt et al., 2000), who administered 
dexamethasone (0.1-5 mg/ Kg/ day) from postnatal day 6 to 9, analyzed VEGF mRNA and 
VEGFR-2 mRNA levels in lungs, and found that VEGF and VEGFR-2 increased with 
increasing doses of dexamethasone. They also analyzed the effects of dexamethasone on the 
amount of mRNA HLF, which has been associated with an increased transcription of VEGF 
in normoxia and hypoxia. In the group treated with 5mg/Kg/day of dexamethasone the 
amount of HLF- in the lung tripled and this could be suggested as a possible mechanism 
accounting for the effects of dexamethasone on lung VEGF mRNA levels. There were no 
differences between dexamethasone and control groups in the study of the VEGF protein. 
Dexamethasone treatment did not alter the pattern of VEGF-expressing cells; mainly distal 
alveolar epithelial cells.  
The different experimental models used, or the fact that the effect of dexamethasone on the 
differentiation of type II cells might lead to a relative increase in VEGF mRNA (Acarregui et 
al., 1999) could explain the discrepancies found in the effect of dexamethasone on VEGF 
expression.  
In our studies (Remesal et al., 2010; San Feliciano et al., 2011) we observed that  
dexamethasone inhibited septation in rats (with postnatal alveolarization), as reported by 
Massaro and Massaro (Massaro et al., 1986). We believe that the effect of dexamethasone on 
the decrease in VEGF may be related to the impairment in alveolarization. 
Also in our studies (Remesal et al., 2010; San Feliciano et al., 2011), we found no decrease in 
VEGF in the group treated with antenatal betamethasone (Fig.1). We have found few studies 
in the literature addressing the effect of betamethasone and VEGF.  
In a study by Aida et al. (Aida et al., 2004) it was reported that VEGF stimulates the expression 
of glucocorticoid receptors, although these might possibly have a more reduced function. 
In an experimental study on sheep, Suzuki et al. (Suzuki et al., 2006) found no differences in 
the levels of VEGF mRNA between the group treated with antenatal betamethasone and the 
group that received no treatment. 
Roubliova et al. (Roubliova et al., 2008) conducted a study that included 112 rabbit foetuses. 
The mothers received 0.05 or 0.1 mg/ Kg/ day of betamethasone at 25 and 26 days of 
gestation, but the mothers of the control group only received saline. The authors studied lung 
VEGF expression and found that VEGF was increased in endothelial cells, epithelial cells, and 
smooth muscle cells, these results being similar to those found in our study. They also 
observed that this effect was dose-dependent. 
5.2 Effects of antenatal glucocorticoids added to oxidative stress damage on the 
pulmonary expression of VEGF and alveolarization 
In our studies (Remesal et al., 2010) we have observed that dexamethasone and hyperoxia 
have an additive effect on the inhibition of VEGF, with a decrease in alveolarization (Fig.1). 
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It has been reported that both factors (dexamethasone and hyperoxia) arrest alveolarization 
(Frank , 1992; Veness-Meehan et al., 2000) 
There are other studies that have reported that hyperoxia and dexamethasone jointly 
enhance decreases in the expression of VEGF (Ozaki et al., 2002; Edelman et al., 1999). 
In the study performed by Ozaki et al. (Ozaki et al., 2002) the authors assessed the response 
of VEGF in the retinas of newborn rabbits after treatment with dexamethasone, exposure to 
hyperoxia with FiO2 0.8 to 1 for 4 days, and exposure to hyperoxia with subsequent recovery 
in air for 5 days. They found that VEGF mRNA was decreased after hyperoxia and recovery 
in air in the animals that had received dexamethasone as compared to animals that had 
received dexamethasone and were in ambient air. 
Edelman et al. (Edelman et al., 1999) used a model of corneal neovascularization induced in 
rat cornea by cauterization. They observed that after cauterization an increase occurred in 
VEGF mRNA and protein produced by leukocytes and macrophages adjacent to the lesion. 
This was a model in which hypoxic zones also occurred around the lesion due to the 
cauterization, and hypoxia could induce the expression of VEGF. They found that treatment 
with dexamethasone or systemic hyperoxia inhibited the increase in VEGF and that 
combined treatment with both dexamethasone and hyperoxia had an additive effect. 
HGF (hepatocyte growth factor) is a growth factor with mitogenic activity against epithelial 
cells. Dexamethasone suppresses the gene expression of HGF and inhibits the growth 
factors responsible for the induction of HGF mRNA expression (Lassus et al., 2002). It has 
also been shown that glucocorticoids inhibit the inflammatory cytokine production. It has 
been shown that interleukin 1 and 6 induce the expression of  HGF in vitro (Tamura et al., 
1993; Zarnegar, 1995). Through its effect on the HGF, dexamethasone exerts an adverse 
influence on lung development and the repair of acute lung injury in the lungs of preterm 
infants (Lassus et al., 2002). 
There is a balance between retinoic acid and glucocorticoids during normal lung 
development. Alterations in this balance produce abnormal alveolarization (Jobe, 2003). It 
has been observed that the survival of newborn rats exposed to oxygen improves with 
concurrent treatment with retinoic acid and dexamethasone, suggesting a possible 
complementary effect (Veness-Meehan et al., 2000). Retinoic acid could compensate the 
acceleration of septal maturation due to the administration of steroids, the benefit of 
treatment with these drugs persisting during epithelial maturation (Bourbon et al., 2005). It 
has also been observed that vitamin A levels in  the blood of ventilated premature children 
whose lung function improved with glucocorticoid treatment were higher (Shenai et al., 
2000).  
According to our own results (Remesal et al., 2010) it would appear that betamethasone 
inhibits the negative action of hyperoxia on VEGF. 
Chandrasekar et al. (Chandrasekar et al., 2008) found that betamethasone reduced intensity 
of oxidative stress and improved the  response of the pulmonary arteries to vasodilators in 
lambs with pulmonary hypertension. They observed that betamethasone increased the 
levels of eNOS and MnSOD.  
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6. VEGF and BPD 
The first definition of BPD was given by Northway in 1967 (Northway et al., 1967) as 
chronic lung disease in childhood as a result of therapy with mechanical ventilation and 
oxygen for respiratory distress syndrome after premature birth. Traditionally, BPD has been 
defined by the persistence of respiratory signs and symptoms, the need for supplemental 
oxygen to treat hypoxemia, and radiographic abnormalities at 36 weeks corrected age. 
In light of the new therapeutic possibilities available today, BPD has been seen to affect very 
immature preterm infants. In the pathogenesis of BDP, the interruption of lung development 
plays a more important role than  volutrauma or inflammation (Jobe, 1999). Alveolar 
hypoplasia and dysmorphic changes of the pulmonary microvasculature have been consistent 
findings in animal models of BPD and in the autopsies of children who died of BPD 
(Maniscalco et al., 2002; Coalson et al., 1988, 1999; Bhatt et al., 2001; De Paepe et al., 2006). 
Among the mechanisms that arrest alveolar development in BPD, the following have been 
implicated: "oxidative stress", mechanical ventilation, proinflammatory factors, 
glucocorticoids, bombesin-like peptides, and poor nutrition (Jobe, 1999; Jobe et al., 2001). 
Premature infants have a non-developed microvasculature and suffer from lung damage 
due to hyperoxia. (Crapo,1986, 2003a, 2003b ; Spyridopoulos et al., 1997). Given the critical 
role of endothelial cells during lung development, strategies that alter the signal of VEGF 
during the foetal and perinatal periods would lead to BPD (Voelkel et al., 2006; Lin et al., 
2005). 
The importance of VEGF in foetal lung growth has led to the vascular theory of BPD, which 
has considerable importance in lung injury due to prematurity, mechanical ventilation, and 
hyperoxia treatment during perinatal life (Abman, 2001; Voelkel et al., 2006). 
The predominant lung histology at autopsy in children with bronchopulmonary dysplasia is 
characterized by an arrest in lung development, including alveolar development and 
vascular growth (Kunig et al., 2005; Lin et al., 2005; Jobe, 1999; Jobe et al., 2001; Abman, 2001; 
Kunig et al., 2006). 
Bhatt  et al. (Bhatt et al., 2001) reported a decrease in the expression of VEGF, VEGFR-1 and 
TIE-2 in the lungs of children who had died of BPD and had dysmorphic capillaries, 
suggesting an arrest of the development of the pulmonary vasculature. 
Ambalavanan and Novak (Ambalavanan et al., 2003) found lower levels of VEGF in the 
tracheal aspirates of preterm infants upon mechanical ventilation in the first 24 hours of life, 
such infants developing BPD in comparison with those who did not develop BPD. The 
results of experimental studies carried out on  rats suggest that the inhibition of VEGF 
receptor activity reduces alveolarization and vascular growth, leading to histological 
changes in the lung that resemble those found in BPD (Lin et al., 2005). 
The decrease of VEGF in BPD has implications for the survival of endothelial cells. In 
addition, VEGF inhibits tumour necrosis factor (TNF-) and hence endothelial cell apoptosis 
(Bhatt et al., 2001). It has also been reported that the inhibition of VEGF receptors in 
immature lungs reduces the expression of nitric oxide synthase (NOS) and the bioactivity of 
NO and later contributes to the development of structural damage and functional BPD 
(Papaioannou et al., 2006; Lin et al., 2005; Tang et al., 2004). 
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The baud et al. (Thebaud et al., 2005) performed intratracheal treatment with gene therapy 
with VEGF to rats exposed to hyperoxia during lung development and observed a longer 
survival and preservation and restoration of normal alveolarization, even when treatment 
was performed with already established BPD. VEGF gene transfer also increased the 
expression of NOS, suggesting that some of the beneficial effects of VEGF could be mediated 
by NO. 
Kunig et al. (Kunig et al., 2005, 2006) treated newborn rats with human recombinant VEGF 
during and after exposure to hyperoxia, observing an increase in vascular growth and 
improved alveolarization. VEGF treatment after the damage caused by hyperoxia in 
neonatal rats improved alveolarization, vascular growth and lung growth, and prevented 
the development of BPD. 
In the above studies (Thebaud et al., 2005; Kunig et al., 2005), VEGF led to highly permeable 
immature capillaries and pulmonary oedema. However, in a combination of gene transfer of 
VEGF and angiopoietin-1, the alveolarization and angiogenesis were preserved and 
improved, with  more mature and fewer permeable capillaries. 
These studies would increase the possibilities for the treatment of children with severe BPD, 
although caution should be exercised on attempting to extrapolate findings from animal 
models for the treatment of human disease. 
In the case of children with BPD, De Paepe et al. (De Paepe et al., 2006) have suggested that 
changes in lung architecture would not simply be due to a decrease in angiogenesis, 
describing an increase in pulmonary capillary density in children who had been subjected to 
mechanical ventilation for long periods. 
Akeson et al. (Akeson et al., 2003) studied transgenic VEGF164-overexpressing mice. They 
noted that when the increased expression of VEGF164 was in the proximal airways the 
abnormalities did not occur at the junction of the vascular network of the lung. When the 
expression of this molecule was higher in the distal airways, there was an alteration of the 
junction of the vascular network, demonstrating that normal pulmonary vascular  
development requires  a precise spatial expression of VEGF-A for proper  morphogenesis, 
and indicating that caution should be exercised in the use of VEGF as a therapeutic agent in 
neonates. 
Changes in the lungs of patients with BPD are similar to those seen in our dexamethasone 
and hyperoxia groups, with fewer and larger alveoli (Remesal et al., 2010;  San Feliciano et 
al., 2011). Betamethasone does not decrease VEGF expression or alveolarization and seems 
to inhibit the negative action of hyperoxia on VEGF (Remesal et al., 2010). 
7. Conclusions 
VEGF is one of the most important growth factors related to lung development and it is 
negatively regulated by oxidative stress. 
With the limitation that we did not use an experimental model to reproduce BPD, the results 
of our studies suggest that repeated administration of antenatal dexamethasone, mainly 
associated with supplemental oxygen therapy, might worsen the morphological changes 
seen in BPD, with a negative effect on lung maturation and VEGF expression until the end 
of the alveolarization period.  
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Our studies also support the notion that betamethasone could be the drug of choice for 
treating pregnant women at risk of preterm delivery. 
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